Lung Cancer Treatment Has Entered Jewelry Retouching

Description of your first forum.
Post Reply
jannatara0801
Posts: 1
Joined: Thu Jul 21, 2022 5:57 am

Lung Cancer Treatment Has Entered Jewelry Retouching

Post by jannatara0801 »

Lung cancer has replaced liver cancer as the "new disease" in Taiwan. Xia Dechun, deputy director of the Department of Internal Medicine of the Hospital Affiliated to China Medical University, said that lung cancer ranks first in cancer mortality in China for 12 consecutive years, and nearly 10,000 people die of lung cancer every year. According to the latest cancer registration report, Among the top 10 cancers in China, lung cancer has the highest incidence rate.According to statistics from the National Health Administration, more than 15,000 people are newly diagnosed with lung cancer every year, of which "lung adenocarcinoma" accounts for 70-80%, and only about 25-30% of patients diagnosed in the early stage. Xia Dechun emphasized that the symptoms of lung cancer are not obvious in the early stage, and when the patient is obviously uncomfortable and seeks a doctor, it is usually in the middle and late stages, and the survival rate is greatly reduced.In the past, patients with advanced lung cancer often developed rapidly due to their condition and had a poor prognosis. In recent years, with the advancement of therapeutic drugs and molecular biology, clinicians can more accurately understand the carcinogenic mechanism of each patient with lung cancer, and thus can identify the cancer-causing mechanism of each patient with various criteria.


Among drugs such as target therapy, chemotherapy and immunotherapy, appropriate and personalized treatment prescriptions are selected for each patient, which greatly improves the treatment effect of lung cancer. Xia Dechun said that in the era when genetic testing was not yet popular, due to the progress of treatment drugs for lung cancer, the treatment strategy changed from traditional integrated application to personalized medicine. Treatment has entered the era of targeted therapy from the past era of random guns and birds, and into the era of targeted therapy in the center of the heart. According to the patient's "biomarkers" and "tumor characteristics", corresponding therapeutic drugs can be given. In addition to better curative effect, the damage to normal cells is relatively small.In fact, targeted drugs are a kind of "precision medicine". After a patient is diagnosed with lung cancer, they need to undergo genetic testing to find out whether they have specific cancer cell genes before they can target specific genes and prescribe the right medicine. He said that the treatment trend strategy of lung adenocarcinoma will first distinguish the type of gene mutation, and then select the target drug according to the type of gene mutation.In recent years, with the advent of "next-generation gene sequencing", the treatment of lung cancer has moved towards a trend of personalized and precise Jewelry Retouching treatment. Precision medicine focuses on whether there is a mutation in a patient's gene, and tailors a treatment plan based on the mutation point of the gene to prolong the patient's life.The most common gene mutations in domestic lung adenocarcinoma are EGFR, KRAS, ALK, etc. Among them, the "EGFR" gene mutation is the most common. About 55-60% of lung adenocarcinoma patients have this gene. Xia Dechun said that EGFR mutation points most often occur in exon 18, 19, 20, and 21, among which exon 19 or 21 are the most common, accounting for about 85-90%. Image He emphasized that patients with EGFR mutations in exon19 or 21 are more fortunate than patients with exon 20 mutations, because the current first to third generation of targeted drugs can allow patients to get the best treatment. The domestic targeted drugs for EGFR gene mutation include the first-generation small molecule targeted drugs Iressa (Iressa) and Tarceva (to relieve), as well as the second-generation Giotrif (Tufuke) and the third-generation Tagrisso (Tiger). Sarah).



In the past, "exon 20" mutations had no corresponding therapeutic drugs. Now, with the advancement of medicine, the advent of a new generation of targeted drugs has brought a first-line life to patients with specific gene mutations of exon 20. This year (2021), the US FDA has approved two EGFR exon 20 mutation-targeted drugs, one of which has also been approved for marketing in China.Xia Dechun believes that next-generation gene sequencing is very important for patients with advanced lung cancer, and more and more effective therapeutic drugs can be found for patients through genetic testing. Lung adenocarcinomas with gene mutations such as EGFR, ALK, ROS1, BRAF, HER2, RET, MET, KRAS, NTRK, etc., already have good targeted drugs to treat, which not only has excellent curative effect, but also has few side effects.Finally, he reminded the public that if there is a family history of lung cancer and a high-risk group of smoking, they should have regular health checks for early diagnosis and early treatment. If the disease is found at an advanced stage, there is no need to be too desperate. Cooperate with the doctor to actively accept the necessary genetic testing and find the most suitable target drug, which will definitely be able to exert the best effect and restore the original quality of life.
Post Reply